Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC)

Iovance Biotherapeutics scheduled a conference call and webcast for October 29, 2026, at 8:30 a.m. ET, to discuss positive clinical data for its one-time lifileucel TIL therapy from Phase 2 IOV-LUN-202 registrational cohorts. The study involves patients with previously treated nonsquamous metastatic non-small cell lung cancer. The company also plans to update investors on precision-based medicine opportunities for its TIL platform in mNSCLC; the article reports no financial results or stock-price movement.